In contrast, for patients with ER+/PR+ disease there was no statistically significant difference in breast cancer mortality between the treatment groups (HR = 0.82, 95% CI 0.63–1.06, p = 0.12) (Figure 5). This evidence concerns the gene ESR1 and breast carcinoma.